Clinical trial
Double-Blind, Placebo-Controlled, Phase 2 Trial to Test Efficacy and Safety of AV-101 (L-4-chlorokynurenine) as Adjunct to Current Antidepressant Therapy in Patients With Major Depressive Disorder (the ELEVATE Study)
NCT03078322 is registered in ClinicalTrials.gov with VistaGen Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Double-Blind, Placebo-Controlled, Phase 2 Trial to Test Efficacy and Safety of AV-101 (L-4-chlorokynurenine) as Adjunct to Current Antidepressant Therapy in Patients With Major Depressive Disorder (the ELEVATE Study)
- Lead sponsor
- VistaGen Therapeutics, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 5, 2018
- Completion date
- October 1, 2019
- Enrollment
- 180 (actual)
- Sites
- 22
Conditions
As the registry lists them; a condition with its own page is linked.